Dyne Therapeutics Inc. (DYN)
10.07
-1.38 (-12.05%)
At close: Mar 31, 2025, 12:32 PM
Dyne Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 506M | 1.37B | 842M | 1.47B | 3M | 3M | 1.58B | 2.32B | 2.47B | 3.55B | 3.1B |
| Cost of Revenue | n/a | 2.46M | 3.35M | 1.09M | 700K | 271K | 24K | 2.93B | 2.28B | 2.03B | 1.15B | 1.15B | 268M | 963M | 1.18B | 1.19B | 1.85B | 2.01B |
| Gross Profit | n/a | -2.46M | -3.35M | -1.09M | -700K | -271K | -24K | -2.43B | -915M | -1.19B | 321M | -1.14B | -265M | 622M | 1.14B | 1.27B | 1.7B | 1.09B |
| Operating Income | -343.89M | -242.16M | -170.96M | -150.03M | -58.65M | -13.83M | -4.79M | -412M | -640M | 64M | -318M | -318M | 714M | -236M | -11M | -834M | 709M | 605M |
| Interest Income | 26.92M | 7.64M | 2.92M | 742K | 56K | 290K | 5K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -317.42M | -235.94M | -168.1M | -149.29M | -59.44M | -14.86M | -4.81M | -538M | -1.29B | -427M | -268M | -417M | 87M | -2.28B | -235M | -1.35B | 246M | 267M |
| Net Income | -317.42M | -235.94M | -165.24M | -149.28M | -58.74M | -13.54M | -4.81M | 76M | -1.24B | 50M | -67M | -356M | 87M | -1.65B | -234M | -1.26B | 174M | 264M |
| Selling & General & Admin | 62.48M | 31.4M | 28.2M | 28.72M | 13.45M | 2.79M | 517K | 189M | 161M | 128M | -97M | 97M | -22M | 135M | 163M | -159M | -157M | -203M |
| Research & Development | 281.41M | 210.76M | 142.76M | 121.31M | 45.2M | 11.04M | 4.28M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Expenses | n/a | n/a | 2.86M | -8K | -790K | -1.32M | -21K | n/a | n/a | n/a | -211M | n/a | -59M | n/a | n/a | -360M | -337M | n/a |
| Operating Expenses | 343.89M | 242.16M | 170.96M | 150.03M | 58.65M | 13.83M | 4.79M | 189M | 161M | 128M | -308M | 97M | -81M | 135M | 163M | -519M | -494M | -203M |
| Interest Expense | n/a | n/a | 2.92M | n/a | 396K | n/a | 5K | 616M | 625M | 546M | 67M | 97M | n/a | 357M | 363M | 415M | 427M | 384M |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | n/a | 242.16M | 170.96M | 150.03M | 58.65M | 13.83M | 4.79M | 3.12B | 2.44B | 2.16B | 837M | 1.24B | 187M | 1.1B | 1.34B | 675M | 1.36B | 1.81B |
| Income Tax | n/a | n/a | -2.86M | -8K | -700K | -1.32M | -11K | -610M | -45M | -474M | 117M | -58M | -627M | -632M | 197M | 315M | -75M | -151M |
| Shares Outstanding (Basic) | 94.14M | 59.68M | 51.98M | 50.9M | 14.4M | 45.42M | 10.32M | 162M | 129M | 125M | 126M | 100M | 100M | 122M | 120M | 1.01B | 870M | 1.76B |
| Shares Outstanding (Diluted) | 94.14M | 59.68M | 51.98M | 50.9M | 14.4M | 45.42M | 10.32M | 162M | 129M | 126M | 126M | 100M | 100M | 122M | 121M | 1.01B | 870M | 1.76B |
| EPS (Basic) | -3.37 | -3.95 | -3.18 | -2.93 | -4.08 | -0.3 | -0.47 | 0.47 | -9.61 | 0.40 | -0.53 | -3.56 | 0.87 | -13.48 | -1.95 | -1.25 | 0.20 | 0.15 |
| EPS (Diluted) | -3.37 | -3.95 | -3.18 | -2.93 | -4.08 | -0.3 | -0.47 | 0.47 | -9.61 | 0.40 | -0.53 | -3.56 | 0.87 | -13.48 | -1.93 | -1.25 | 0.20 | 0.15 |
| EBITDA | -343.89M | -233.48M | -164.75M | -148.2M | -58.34M | -14.59M | -4.79M | 949M | 106M | 736M | 292M | 150M | 113M | -1.57B | 734M | -173M | 902M | 830M |
| Depreciation & Amortization | n/a | 2.46M | 3.35M | 1.09M | 700K | 271K | 24K | 867M | 766M | 614M | 292M | 467M | 26M | 346M | 408M | 359M | 376M | 333M |